Pathway to Cures

The National Bleeding Disorders Foundation’s Pathway to Cures takes a targeted and selective approach to investment opportunities, partnering with companies that meet four primary criteria: Innovation, Mission Impact, Partnerships, and Financial Return Potential. ▪ Innovation: P2C will invest in new therapeutic approaches at any stage of the R&D continuum from discovery through the clinic if they show potential to significantly improve a patient’s quality of life. ▪ Mission Impact: P2C will focus on investing in therapies and technologies that align with our mission to accelerate transformational change for people living with inheritable blood and bleeding disorders. ▪ Partnerships: P2C will partner with venture capital, biotech, and pharma companies, among others, to close the funding gap for early-stage pipeline development, charting a new pathway for cures and innovative therapies. ▪ Financial Return Potential: P2C will only consider partnering with and investing in companies that are financially viable and offer the potential of a return on investment. Having an investible business model is a key criterion that must be met to bring in outside capital and fuel future opportunities for the Fund to create transformational change.